Keros Therapeutics, Inc. Retained Earnings
Keros Therapeutics, Inc. (KROS) had Retained Earnings of -$534.18 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-03
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$534.18M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$505.47M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$481.76M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$458.30M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$534.18M 10-Q · filed 2026-08-03 |
| 2026-03-31 | -$505.47M 10-Q · filed 2026-05-14 |
| 2025-12-31 | -$481.76M 10-Q · filed 2026-08-03 |
| 2025-09-30 | -$458.30M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$451.02M 10-Q · filed 2025-08-06 |
| 2025-03-31 | -$420.33M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$568.78M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$522.75M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$469.80M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$424.54M 10-Q · filed 2024-05-08 |
| 2023-12-31 | -$381.43M 10-K · filed 2025-02-26 |
| 2023-09-30 | -$341.18M 10-Q · filed 2023-11-06 |
| 2023-06-30 | -$301.74M 10-Q · filed 2023-08-07 |
| 2023-03-31 | -$264.24M 10-Q · filed 2023-05-04 |
| 2022-12-31 | -$228.43M 10-K · filed 2024-02-28 |
| 2022-09-30 | -$198.72M 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$175.21M 10-Q · filed 2022-08-04 |
| 2022-03-31 | -$147.94M 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$123.75M 10-K · filed 2023-03-03 |
| 2021-09-30 | -$116.81M 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$96.52M 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$80.90M 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$65.01M 10-K · filed 2022-03-09 |
| 2020-09-30 | -$54.34M 10-Q · filed 2020-11-10 |
| 2020-06-30 | -$42.30M 10-Q · filed 2020-08-13 |
| 2020-03-31 | -$31.54M 10-Q · filed 2020-05-22 |
| 2019-12-31 | -$19.65M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |